<DOC>
	<DOCNO>NCT02399046</DOCNO>
	<brief_summary>A clinical trial total knee system use Primary Total Knee Arthroplasty China .</brief_summary>
	<brief_title>A Clinical Trial Study Knee System Primary Total Knee Arthroplasty China</brief_title>
	<detailed_description>A prospective , Randomized , Multicenter , Controlled Study Comparing Outcomes Primary Total Knee Arthroplasty Devices Manufactured China versus Devices Manufactured Outside China .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>1. . The subject ≥18years old 2. . The Subject must Chinese ethnic descent willing return three occasion clinical evaluation . 3. . Subject suitable candidate cement primary TKA use device describe CIP either resurface nonresurfaced patella . 4. . Subject must meet criterion specify BOTH China Knee stem P.F.C.® Sigma knee instruction use ( IFU ) 5. . Before surgery , subject willing able sign inform consent form approve Institutional Review Board ( IRB ) , Ethics Committee ( EC ) Ethical Review Board ( ERB ) . 6. . Subject , opinion Clinical Investigator , able understand clinical investigation cooperate investigational procedure . 7. . Subject must comfortable speaking , reading , understand question provide response available translated language patient report outcomes ( PROs ) CIP . 8. . Subject receive unilateral knee replacement , contralateral knee replacement anticipate , surgery must occur within 6 month first study knee TKA . The second knee enrol study . 1 . Subject provide write voluntary consent participate clinical study . 2 . The Subject woman pregnant lactating . 3 . Subject anticipated require contralateral TKA 6 month 1 year . 4 . Contralateral knee already enrol study . 5 . Previous partial knee replacement ( unicompartmental , bicompartmental patellofemoral joint replacement ) , patellectomy , high tibial osteotomy primary TKA affect knee . 6 . Subject malignant disease , severe condition , alcohol drug addiction and/or mental disorder investigator believe interfere study participation . 7 . Subjects severe osteoporosis , metabolic bone disease , radioactive bone disease tumor bone surround knee joint , opinion investigator , negatively impact implant fixation outcome investigation 8 . Subject significant neurological musculoskeletal disorder disease may adversely affect gait weight bearing ( e.g . muscular dystrophy , multiple sclerosis , cerebral infarction , hemiplegia , Charcot disease ) . 9 . Subject comfortable speaking , reading , understand question provide response available translated language PROs CIP . 10 . Subject medical condition le 2 year life expectancy . 11 . The Subject comorbid condition ( ) could limit Subject 's ability participate study , compliance followup requirement impact scientific integrity study . 12 . The Subject currently participate another investigational drug device study . 13 . Subject prisoner . 14 . The Subject know allergy implant component ( metal example ) . 15 . Hemoglobin &lt; 11 g/L 16 . Albumin &lt; 90 % normal low limit 17 . CRP &gt; 2 time normal upper limit 18 . ESR &gt; 2 time normal upper limit 19 . Subjects abnormal coagulation exam result correct drug plasma replacement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>